{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+acetate+1000+mg&page=4", "query": { "intervention": "Abiraterone acetate 1000 mg", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 82, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+acetate+1000+mg&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+acetate+1000+mg&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T23:43:05.678Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00887198", "title": "Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1088, "start_date": "2009-04-28", "completion_date": "2017-05-25", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-10T23:43:05.678Z", "location_count": 48, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bellflower", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Marina del Rey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00887198" }, { "nct_id": "NCT02268175", "title": "Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Prostate Cancer", "High Risk Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 75, "start_date": "2014-10", "completion_date": "2021-12", "has_results": true, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-10-10T23:43:05.678Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Seattle, Washington", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02268175" }, { "nct_id": "NCT04493853", "title": "Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hormone-Sensitive Prostate Cancer" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Abiraterone Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "MALE", "summary": "18 Years to 130 Years · Male only" }, "enrollment_count": 1012, "start_date": "2020-07-13", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-10T23:43:05.678Z", "location_count": 33, "location_summary": "Tucson, Arizona • La Jolla, California • Orange, California + 29 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493853" }, { "nct_id": "NCT03732820", "title": "Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "olaparib", "type": "DRUG" }, { "name": "abiraterone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 895, "start_date": "2018-10-31", "completion_date": "2027-02-05", "has_results": true, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-10T23:43:05.678Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Clovis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03732820" }, { "nct_id": "NCT01017939", "title": "A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Neoplasms" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Dextromethorphan hydrobromide", "type": "DRUG" }, { "name": "Theophylline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 34, "start_date": "2010-01", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2013-04-12", "last_synced_at": "2026-10-10T23:43:05.678Z", "location_count": 4, "location_summary": "Beverly Hills, California • San Antonio, Texas", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01017939" }, { "nct_id": "NCT00600535", "title": "A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Neoplasms" ], "interventions": [ { "name": "Stage 1 Group 1: abiraterone acetate", "type": "DRUG" }, { "name": "Stage 1 Group 2: abiraterone acetate", "type": "DRUG" }, { "name": "Stage 2: abiraterone acetate", "type": "DRUG" }, { "name": "Stage 3: abiraterone acetate", "type": "DRUG" }, { "name": "Stage 3: glucocorticoid", "type": "DRUG" }, { "name": "Stage 4: abiraterone acetate", "type": "DRUG" }, { "name": "Stage 4: glucocorticoid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cougar Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 31, "start_date": "2007-07", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2013-04-17", "last_synced_at": "2026-10-10T23:43:05.678Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00600535" }, { "nct_id": "NCT02230046", "title": "Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Abiraterone acetate (Treatment A)", "type": "DRUG" }, { "name": "Abiraterone acetate (Treatment B)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 102, "start_date": "2014-10", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2016-01-20", "last_synced_at": "2026-10-10T23:43:05.678Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02230046" }, { "nct_id": "NCT01637402", "title": "A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Terence Friedlander, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 41, "start_date": "2013-03-13", "completion_date": "2017-02-27", "has_results": true, "last_update_posted_date": "2020-08-17", "last_synced_at": "2026-10-10T23:43:05.678Z", "location_count": 2, "location_summary": "San Francisco, California • Portland, Oregon", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01637402" }, { "nct_id": "NCT01961843", "title": "Abiraterone Acetate for Castrate Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2014-01-14", "completion_date": "2024-05-31", "has_results": false, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-10-10T23:43:05.678Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01961843" }, { "nct_id": "NCT00485303", "title": "An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms", "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cougar Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 58, "start_date": "2007-06", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-10-10T23:43:05.678Z", "location_count": 12, "location_summary": "Los Angeles, California • San Francisco, California • Baltimore, Maryland + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00485303" } ] }